Roche, Genentech place a $100M bet on fibrosis, nabbing PhII program from Kiniksa
As parent company Roche aims to secure a place in the allogeneic CAR-T therapy race, Genentech is spinning its own deal to jump into fibrosis with a program from Kiniksa.
Genentech shelled out $80 million in upfront cash and another $20 million in near-term payments to license Kiniksa’s vixarelimab, formerly known as KPL-716, and shepherd it into new clinical studies, the companies announced Wednesday. If all the milestones are achieved, Kiniksa could stand to gain another $600 million. Investor reaction to the deal was muted, as Kiniksa shares $KNSA were up about 1% in pre-market trading Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
